Please login first

List of accepted submissions

 
 
Show results per page
Find papers
 
  • Open access
  • 36 Reads
Optimization of Urea Formation with Phoxime™ Resin using the Nautilus™ 2400
Phosgenated p-nitrophenyl(polystyrene)ketoxime (Phoxime™) resin (1) has been previously utilized as a latent isocyanate equivalent. The Nautilus™ 2400 automated organic synthesizer was used to determine the optimal temperature for thermolysis of the polymer-bound oxime-carbamate derived from Phoxime resin and subsequent amine addition to give a urea in solution.
  • Open access
  • 50 Reads
Trapping of Nucleophiles by Rink Resin
Commonly, molecules synthesized on a solid support are attached to the solid phase by a linker entity, often an acid labile linker. A commonly used acid labile linker is the "Rink-linker"1 which provides solid phase attachment via an amide or an ester bond. Upon acid treatment target molecules are released, which all bear a "trace of the linker", such as an acid or primary amide functionality. Here, we describe a method to constitute a much wider variety of molecules by trapping a "Rink-cation" with a number of alcohols, amines or thiols.
  • Open access
  • 56 Reads
Synthesis of a Photolabile `Safety Catch' Linker of the 3'-Methoxybenzoin Type
, ,
Solid supports carrying a photolabile linker of the 3'-methoxybenzoin type were prepared by a rapid solid phase synthesis method. Alternatively, the linker was preassembled in solution by a more lengthy procedure and then coupled onto polystyrene via its carboxymethyl handle. `Safety catch' linkers of this type are expected to play an important role for the preparation of combinatorial libraries suitable for a variety of miniaturized screening methods, where `reagentless' release of compounds from the carrier is crucial
  • Open access
  • 35 Reads
9-(2-Hydroxypropyl)adenine: A Novel Fraudulent Substrate of HSV1-Thymidine Kinase. An Interdisciplinary Study
, , , , , , ,
Herpes Simplex virus type 1 thymidine kinase (HSV1 TK) phosphorylates thymidine (dT) to thymidine monophosphate (dTMP) playing a key role in reactivation from the latency and replication of herpes simplex viruses. Acyclovir (ACV) and gancyclovir (GCV) are today the only therapeutic compounds to interfere with a severe HSV infection. Those molecules act as fraudulent substrates blocking virus proliferation by dead end complexes with the viral DNA after being activated by the HSV-specific TK. Furthermore, HSV1 TK was more recently used as a suicide enzyme in gene therapy of cancer (1,2) and AIDS (3) in combination with ACV. The molecular basis of the selective therapy, that uses HSV1 TK as target, is the difference in substrate specificity between the human cellular and the herpesviral TK isoenzymes. Because of the important therapeutic implications, HSV is not only linked to viral infection but also with other diseases such as Kaposi's Sarcoma (4) and Alzheimer disease (5), and the increase of resistance towards ACV and GCV, intensive efforts have been directed towards the search of new compounds with general antiviral activity (6). In this study we report the results of a first cycle of structure-based drug-design aiming the development of new compounds for antiviral and gene therapy.
Top